Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (221-230 of 241) with videos related to

Pageof 25
Sort By:
Clinical Pharmacology and Therapeutics|June 18, 2024
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and OlderShigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, et al.
Journal of Gastroenterology|March 4, 2020
Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesKazuyuki Mizuno, Takanori Ito, Masatoshi Ishigami, et al.
World Journal of Gastroenterology|December 10, 2021
Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survivalKentaro Yamada, Tsunaki Sawada, Masanao Nakamura, et al.
Nagoya Journal of Medical Science|June 27, 2019
Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II studyNao Takano, Suguru Yamada, Akihiro Hirakawa, et al.
Journal of the Endocrine Society|March 31, 2018
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective StudyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
International Journal of Clinical Oncology|July 15, 2023
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, et al.
The Oncologist|July 28, 2018
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)Goro Nakayama, Ayako Mitsuma, Yuki Sunagawa, et al.
Hepatology International|August 10, 2021
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignanciesTakanori Ito, Masatoshi Ishigami, Takafumi Yamamoto, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2022
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 BlockadeTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
Journal for Immunotherapy of Cancer|July 2, 2020
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective studyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
Pageof 25

Showing results (221-230 of 241) with videos related to

Sort By:
Pageof 25
Clinical Pharmacology and Therapeutics|June 18, 2024
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and OlderShigehiro Yagishita, Yuta Yamanaka, Takayasu Kurata, et al.
Journal of Gastroenterology|March 4, 2020
Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignanciesKazuyuki Mizuno, Takanori Ito, Masatoshi Ishigami, et al.
World Journal of Gastroenterology|December 10, 2021
Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survivalKentaro Yamada, Tsunaki Sawada, Masanao Nakamura, et al.
Nagoya Journal of Medical Science|June 27, 2019
Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II studyNao Takano, Suguru Yamada, Akihiro Hirakawa, et al.
Journal of the Endocrine Society|March 31, 2018
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective StudyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
International Journal of Clinical Oncology|July 15, 2023
Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022Yuichi Ando, Hiroyuki Nishiyama, Hideki Shimodaira, et al.
The Oncologist|July 28, 2018
Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)Goro Nakayama, Ayako Mitsuma, Yuki Sunagawa, et al.
Hepatology International|August 10, 2021
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignanciesTakanori Ito, Masatoshi Ishigami, Takafumi Yamamoto, et al.
The Journal of Clinical Endocrinology and Metabolism|August 2, 2022
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 BlockadeTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
Journal for Immunotherapy of Cancer|July 2, 2020
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective studyTomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
Pageof 25